Small Cell Lung Cancer
Advertisement
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
A project led by a researcher from the Dana-Farber Cancer Center is the first to receive the four-year grant of $2.5 million.
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
The initiative is promoting lung cancer screening and efforts to fund research, as well as releasing an upcoming report.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness.
The campaign, titled "Anyone with Lungs Can Get Lung Cancer," includes multiple virtual and in-person components.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The meeting will be held September 12-15, 2026, in Seoul, South Korea.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.